

RCE of Serial No. 09/400,492

-2-

Group Art Unit: 1646

NOs: 14, 16, 18, 20, 22, 24, 26, and 28, in the presence and absence of a candidate compound, and

b) determining whether the presence of the candidate compound modulates the interaction of the potassium channel or fragment thereof with said 9q PCIP polypeptide, thereby identifying a compound suitable for treating a cardiovascular disorder.

19. **(Amended)** A method for identifying a compound suitable for treating a cardiovascular disorder, comprising:

a) incubating a cell expressing i) a potassium channel comprising a Kv4.3 or Kv4.2 subunit, or a fragment thereof that functions as a potassium channel, and ii) a biologically active fragment of a 9q PCIP polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 16, 18, 20, 22, 24, 26, and 28, wherein said biologically active fragment is selected from the group consisting of an EF domain, residues 68-252 of human 9q, and a Kv4.3 or Kv4.2 potassium channel α subunit binding domain, in the presence and absence of a candidate compound; and

b) determining whether the presence of the candidate compound modulates the interaction of the potassium channel or fragment thereof with said biologically active fragment of said 9q PCIP polypeptide, thereby identifying a compound suitable for treating a cardiovascular disorder.

25. **(Amended)** A method for identifying a compound suitable for treating a cardiovascular disorder comprising:

a) contacting a polypeptide that is at least 95% identical to a 9q PCIP polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 16, 18, 20, 22, 24, 26, and 28 and retains a the ability to bind to a Kv4 channel, or a cell expressing said polypeptide with a test compound; and

b) determining whether said polypeptide binds to said test compound, thereby identifying a compound suitable for treating a cardiovascular disorder.